Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Nonbenzamidine compounds as selective factor Xa inhibitors.

W He1, B Hanney, M R Myers

  • 1Department of Medicinal Chemistry, Aventis Pharmaceuticals, Collegeville, PA 19426, USA. wei.he@aventis.com

Bioorganic & Medicinal Chemistry Letters
|August 11, 2000
PubMed
Summary

Nonbenzamidine compounds, including imidazole, pyridine, pyrimidine, and thiazole derivatives, show promise as selective inhibitors of serine protease factor Xa. These compounds offer a potential therapeutic avenue for conditions involving factor Xa activity.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Sustaining work ability amongst female professional workers with long COVID.

Occupational medicine (Oxford, England)·2024
Same author

Pharmacological characterization of a novel factor Xa inhibitor, FXV673.

Thrombosis research·2001
Same author

Role of short-term inhibition of factor Xa by FXV673 in arterial passivation: a study in a chronic model of thrombosis in conscious dogs.

Journal of cardiovascular pharmacology·2001
Same author

Recombinant chemosensory protein (CSP2) from the moth Mamestra brassicae: crystallization and preliminary crystallographic study.

Acta crystallographica. Section D, Biological crystallography·2001
Same author

Multiparameter analysis of human epithelial tumor cell lines by laser scanning cytometry.

Cytometry·2001
Same author

Congenital nasal pyriform aperture stenosis.

The Journal of the Louisiana State Medical Society : official organ of the Louisiana State Medical Society·2000

Area of Science:

  • Medicinal Chemistry
  • Biochemistry
  • Pharmacology

Background:

  • Serine proteases, particularly factor Xa, play crucial roles in physiological processes such as blood coagulation.
  • Dysregulation of factor Xa activity is implicated in various thrombotic disorders.
  • Development of selective inhibitors is critical for targeted anticoagulant therapy.

Purpose of the Study:

  • To discuss the development and potential of nonbenzamidine compounds as selective inhibitors of serine protease factor Xa.
  • To explore the structure-activity relationships of imidazole, pyridine, pyrimidine, and thiazole derivatives targeting factor Xa.
  • To evaluate the therapeutic implications of these novel inhibitors.

Main Methods:

  • Synthesis and characterization of novel nonbenzamidine derivatives.

Related Experiment Videos

  • In vitro enzymatic assays to determine inhibitory potency against factor Xa.
  • Structure-based drug design and computational modeling.
  • Evaluation of selectivity against other serine proteases.

    • Main Results:

    • Several nonbenzamidine derivatives, including imidazole, pyridine, pyrimidine, and thiazole scaffolds, demonstrated potent and selective inhibition of factor Xa.
    • Structure-activity relationship studies identified key pharmacophoric features responsible for high affinity and selectivity.
    • These compounds exhibited favorable pharmacokinetic profiles in preliminary assessments.

    Conclusions:

    • Nonbenzamidine compounds represent a promising class of selective factor Xa inhibitors.
    • The identified derivatives hold potential for the development of novel anticoagulant agents.
    • Further preclinical and clinical investigations are warranted to explore their therapeutic efficacy and safety.